| Issue |
Med Sci (Paris)
Volume 39, Number 6-7, Juin-Juillet 2023
|
|
|---|---|---|
| Page(s) | 575 - 577 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/2023076 | |
| Published online | 30 June 2023 | |
Nouveau et (beaucoup) plus cher – Meilleur ?
Chroniques génomiques
New, more expensive - Not necessarily better
Biologiste, généticien et immunologiste, président d’Aprogène (association pour la promotion de la génomique), 13007 Marseille, France
Abstract
The prices of new oncology drugs are frequently above 100,000 US dollars, and this does not generally correlate with significantly improved clinical efficacy. In the absence of effective regulation and of real competition, companies tend to charge « what the market can bear ». Regulatory intervention is required, notably at the EU level.
© 2023 médecine/sciences – Inserm
Article publié sous les conditions définies par la licence Creative Commons Attribution License CC-BY (https://creativecommons.org/licenses/by/4.0), qui autorise sans restrictions l'utilisation, la diffusion, et la reproduction sur quelque support que ce soit, sous réserve de citation correcte de la publication originale.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.